ArticleFrontiers in pharmacology2024

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG

Ya-Ning Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.